Korea S.E.
18:00:00 2024-05-30 EDT
5-day change
1st Jan Change
6,590
KRW
+0.30%
-0.45%
-11.31%
Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on December 6, 2018 has closed with 1,000,000 shares, representing 1.91% for KRW 7,098.83 million.
The company closed its plan on March 5, 2019.
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-16
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
03-18
CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea
01-29
MT
Bioleaders Corporation announced that it has received KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.
01-01
CI
Bioleaders Corporation announced that it expects to receive KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.
12-28
CI
Kwang Dong Pharmaceutical Co., Ltd. agreed to acquire a 58.73% stake in BL Healthcare Corp. from BL Healthcare Corp. for KRW 30 billion
12-28
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-14
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-14
CI
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 11, 2023.
23-06-30
CI
Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on April 11, 2023, has closed with 1,000,000 shares, representing 2.43% for KRW 6,228.66 million.
23-06-27
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
Kwang Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,000,000 shares.
23-04-11
CI
Kwang Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
23-04-10
CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Commercialize Myopia Drug in South Korea
23-03-27
MT
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-14
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-15
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-16
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-17
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
21-11-15
CI
Oxford Cancer Biomarkers Ltd announced that it has received funding from Kwang Dong Pharmaceutical Co., Ltd.
19-06-02
CI
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 6, 2018.
19-03-05
CI
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 6, 2018.
19-03-05
CI
Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on December 6, 2018 has closed with 1,000,000 shares, representing 1.91% for KRW 7,098.83 million.
19-03-04
CI
Kwang Dong Pharmaceutical Co., Ltd. announces an Equity Buyback.
18-12-06
CI
Kwang Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
18-12-05
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Kwangdong Pharmaceutical Co Ltd is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company operates its business through five segments. The Mineral Water Business segment supplies drinking spring water under Samdasoo brand. The Distribution Business segment distributes health drinks under brand names of Vita500 and Corn Silk Tea. The Pharmacy Business segment provides Chinese prescription cold medicines, hypertension medicines, cerebral apoplexy medicines and health drinks. The Hospital Business segment offers anticancer agents, blood vessel adjuvants, vitamin D injections and others. The Other segment provides products which not covered by Pharmacy, Hospital and Distribution segments.
More about the company
1st Jan change
Capi.
-11.31% 191M +15.91% 41.97B +22.40% 22.34B +18.48% 15.25B +16.12% 14B +45.12% 12.06B -0.05% 6.79B -9.58% 6.8B -8.87% 5.73B +14.18% 5.49B
Generic Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
KWANG DONG PHARMACEUTICAL CO., LTD. 
